ABVC Biopharma Inc
ABVC BioPharma, Inc., a clinical-stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials as a combination therapy for triple negative breast cancer; ABV-1504, which has completed Phase II clinical trials for depressive disorders; ABV-1505, which is in Phase II … Read more
ABVC Biopharma Inc (ABVC) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of December 2025: 0.140x
Based on the latest financial reports, ABVC Biopharma Inc (ABVC) has a cash flow conversion efficiency ratio of 0.140x as of December 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($1.86 Million) by net assets ($13.30 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
ABVC Biopharma Inc - Cash Flow Conversion Efficiency Trend (2002–2025)
This chart illustrates how ABVC Biopharma Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
ABVC Biopharma Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of ABVC Biopharma Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Adyton Resources Corporation
PINK:ADYRF
|
0.004x |
|
Arena Group Holdings Inc
NYSE MKT:AREN
|
-1.170x |
|
Crown Confectionery Co Ltd
KO:264900
|
-0.003x |
|
Ulusoy Elektrik Imalat
IS:ULUSE
|
4.666x |
|
Yuyu Pharma Inc
KO:000227
|
0.006x |
|
Malaysian Bulk Carriers Bhd
KLSE:5077
|
0.000x |
|
CIFI Holdings (Group) Co. Ltd
F:6CI
|
0.064x |
|
Ebebek Magazacilik Anonim Sirketi
IS:EBEBK
|
0.354x |
Annual Cash Flow Conversion Efficiency for ABVC Biopharma Inc (2002–2025)
The table below shows the annual cash flow conversion efficiency of ABVC Biopharma Inc from 2002 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $13.30 Million | $-2.99 Million | -0.225x | +91.01% |
| 2024-12-31 | $723.96K | $-1.81 Million | -2.499x | +25.19% |
| 2023-12-31 | $1.25 Million | $-4.19 Million | -3.340x | -107.25% |
| 2022-12-31 | $4.59 Million | $-7.40 Million | -1.612x | -88.16% |
| 2021-12-31 | $8.87 Million | $-7.60 Million | -0.857x | -9.27% |
| 2020-12-31 | $5.82 Million | $-4.56 Million | -0.784x | -103.12% |
| 2019-12-31 | $-124.82K | $-3.13 Million | 25.113x | +22811.16% |
| 2018-12-31 | $-5.75 Million | $-630.20K | 0.110x | +116.02% |
| 2017-12-31 | $2.46 Million | $-1.68 Million | -0.684x | -228.39% |
| 2016-12-31 | $-6.52 Million | $-3.47 Million | 0.533x | +361.25% |
| 2015-12-31 | $29.08K | $3.36K | 0.116x | +202.37% |
| 2014-12-31 | $30.56K | $1.17K | 0.038x | -96.49% |
| 2011-12-31 | $-1.46 Million | $-1.59 Million | 1.088x | +211.17% |
| 2010-12-31 | $-2.99 Million | $-1.05 Million | 0.350x | -54.80% |
| 2009-12-31 | $-2.01 Million | $-1.56 Million | 0.774x | -58.93% |
| 2008-12-31 | $-1.24 Million | $-2.34 Million | 1.884x | +120.31% |
| 2007-12-31 | $290.29K | $-2.69 Million | -9.277x | -1438.21% |
| 2006-12-31 | $35.27K | $24.45K | 0.693x | +328.26% |
| 2005-12-31 | $60.67K | $-18.43K | -0.304x | -256.26% |
| 2004-12-31 | $87.34K | $-7.45K | -0.085x | -2021.11% |
| 2003-12-31 | $80.00K | $355.00 | 0.004x | +100.44% |
| 2002-12-31 | $10.00K | $-10.00K | -1.000x | -- |